Over 30 million people in the U.S. are affected by more than 10,000 rare diseases, with about half of these individuals being children. Many rare diseases are life-threatening and lack approved treatments. The FDA aims to engage patients and caregivers to incorporate their perspectives into the review of medical products for rare disease patients.

Recent advances in drug target identification and gene therapies are promising for rare disease treatment. In 2023, over half of the novel drugs and biologics approved by the FDA’s CDER and CBER were for rare diseases. Despite these advances, many rare diseases still lack treatment options, requiring new approaches for the development and approval of safe and effective drugs.

To address these needs, the FDA plans to establish a Rare Disease Innovation Hub with three primary functions:

  1. Single Point of Engagement: The Hub will serve as a central connection for the rare disease community, including patients, caregivers, trade organizations, and scientific/academic groups. It will help navigate intersections across the FDA, such as medical devices and combination products.
  2. Enhanced Intercenter Collaboration: The Hub will promote collaboration to address common scientific, clinical, and policy issues in rare disease product development. It will also ensure consistency across FDA offices and Centers.
  3. Advancement of Regulatory Science: Dedicated workstreams will focus on novel endpoints, biomarker development, innovative trial design, real-world evidence, and statistical methods to advance regulatory science.

The Hub aims to leverage cross-agency expertise and enhance connectivity to spur the development of treatments for rare diseases, particularly those with smaller populations or variable natural histories.1

Read the full text here.

References

  1. Research, C. F. D. E. A. (2023, August 29). Rare Diseases Team. U.S. Food And Drug Administration. https://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-diseases-team

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred